Over the course of our nearly seven-year partnership with Custopharm, we elevated the company into a high-value franchise featuring a robust portfolio of highly differentiated generic products, primarily injectables. Working with leadership, we invested in recruiting an experienced scientific team supported by a global network of supply and contract manufacturing partners, built a state-of-the-art research and development laboratory, and launched a commercial arm. The result: Custopharm attained a prolific output of 13 product approvals, including four first-to-market ANDA approvals and a competitive generic therapy designation, in six years. The company also grew its pipeline with eight additional products in development or pending approval. In 2022, Hikma Pharmaceuticals acquired Custopharm to expand its product portfolio and enhance its R&D capabilities.

Subscribe to Water Street News

To receive Water Street news via email,
please complete the form below.

Privacy Policy

You’ve just been sent an email to confirm your email address. Please click on the link in the email to activate your subscription.

If you do not receive an email from us within a few minutes, please check your spam folder. If our email did not come through to you, please click on this link,

Something went wrong. If you are seeing this error, please let us know, and we will get it fixed asap.